Contact a rep button
contact a rep

stay connected!

Fill in the required fields to stay up to date with news and announcements about VPRIV.
*Required Field

One or more required fields are invalid.

Please review and submit this form again.

thank you!

You have been successfully signed up to receive
communications from Takeda

Click here to unsubscribe

VPRIV READY

JOHN — GERIATRIC PATIENT*

*Patient profiles for illustrative purposes only and do not depict actual patients

older male patient

John was diagnosed with type 1 Gaucher disease at the age of 55.

John and his physician discussed treatment options, and they decided together that VPRIV was right for him. Throughout the years, John has continued to receive his VPRIV infusions once every other week.2 John used to have his infusions at a treatment center but then decided to receive them at home, where he is more comfortable. When John retired, he wanted to travel abroad with his family. As he informed his physician in advance, they were able to devise a plan with suitable arrangements that supported his therapeutic needs while he was traveling.

In recent years, John has been diagnosed with a heart condition and high blood pressure, for which he needs prescription medication. Despite these new medications, John’s doctor advised that he was able to continue to receive his VPRIV treatment, as VPRIV does not have any associated drug–drug interactions listed on the Prescribing Information.2

consider
  • VPRIV has been evaluated during clinical trials in 56 older patients (≥65 years, including 10 patients ≥75 years)2
  • No drug–drug interactions or contraindications are listed with VPRIV, as per the Prescribing Information2

CLICK ON EACH PATIENT BELOW TO READ THEIR STORY:

These are hypothetical patient profiles intended to represent patients with type 1 Gaucher disease

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate VPRIV in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment.